Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918929 | 1.00 | FEN1 (0.46) | FEN1DAOKDM4ELMNAHPGD | |
| SCHEMBL578429 | 0.86 | KDM4E (0.50) | FEN1DAOKDM4ELMNAHPGD | |
| SCHEMBL30918936 | 0.81 | PARP1 (0.55) | DAOKDM4ELMNAHPGDALDH1A1 | |
| SCHEMBL3037553 | 0.81 | PARP1 (0.55) | DAOKDM4ELMNAHPGDALDH1A1 | |
| SCHEMBL30918927 | 0.78 | JUN (0.56) | HPGDALDH1A1MEN1KMT2ACDK4 | |
| SCHEMBL1747975 | 0.76 | ALPL (0.56) | ALDH1A1 | |
| SCHEMBL578054 | 0.74 | PARP14 (0.46) | DAOKDM4ELMNAHPGDPARP1 | |
| SCHEMBL30918930 | 0.73 | PARP1 (0.56) | DAOLMNAHPGDALDH1A1MEN1 | |
| SCHEMBL577953 | 0.73 | NPC1 (0.52) | KDM4ELMNAHPGDALDH1A1MEN1 | |
| SCHEMBL30014118 | 0.73 | NPC1 (0.52) | KDM4ELMNAHPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | COASY, LSS, INF2 | FEN1 4265/4885DAO 1052/4885KDM4E 2092/4885 |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | CCNL2, ASH2L, AHR | FEN1 4398/4885DAO 736/4885KDM4E 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.